24/7 Market News Snapshot 18 September, 2024 – BioCardia, Inc. Common Stock (NASDAQ:BCDA)

September 18, 2024

DENVER, Colo., 18 September, 2024 (247marketnews.com) – (NASDAQ:BCDA) are discussed in this article.
BioCardia, Inc. has demonstrated remarkable momentum in the financial markets, with its stock price climbing to $3.04 today, an increase of approximately 8.96% from the previous close of $2.79. This upward trend is underscored by a trading volume of 978.88K shares, reflecting robust investor interest and potential market validation for the company. Analysts suggest that should this trajectory persist, BioCardia may face resistance around $3.50, while a support level is anticipated near $2.90, necessitating close monitoring of volume trends and price actions to assess the sustainability of this bullish movement.

In a parallel development, BioCardia has achieved a significant milestone by regaining full compliance with the Nasdaq Capital Market’s Listing Requirements. As affirmed by Nasdaq on September 17, 2024, this compliance follows a previous determination from a Hearing Panel, which recognized the company’s adherence to financial standards in light of successful capital raising efforts.

Peter Altman, PhD, the company’s President and CEO, emphasized that these advancements mark a pivotal juncture for BioCardia. With the recent FDA approval of the CardiAMP® Cell Therapy Heart Failure II protocol amendment and advancements in clinical trials, BioCardia is poised to enhance its mission of developing innovative therapies for cardiovascular and pulmonary ailments. The company has also achieved FDA market clearance for its Morph® DNA™ product family and executed a successful $7.2 million financing round to bolster ongoing projects.

As BioCardia continues to refine the CardiAMP HF I trial data and prepare for patient randomization in the pivotal CardiAMP HF II trial, its commitment to advancing cellular therapies remains resolute, aimed at revolutionizing treatment options for patients suffering from cardiovascular and pulmonary conditions.

Related news for (BCDA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.